Literature DB >> 3561434

An examination of some factors influencing creatine kinase in the blood of patients with muscular dystrophy.

M J Jackson, J M Round, D J Newham, R H Edwards.   

Abstract

The natural variability of plasma creatine kinase activity has been examined in patients suffering from muscular dystrophy and in normal subjects. The coefficient of variation of the plasma creatine kinase activities was found to be large (approximately 35%) in both patients with Duchenne muscular dystrophy and normal control subjects. A comparison of the plasma activities of creatine kinase with other muscle-derived enzymes suggests that the cause of this variability is changes in the release of enzymes from muscle. Data obtained concerning the effect of physical activity on plasma creatine kinase activity are contradictory, but several young patients with Duchenne muscular dystrophy and a very high creatine kinase activity (greater than 5000 IU/liter) showed a decreased activity following admission to hospital. An estimate of the rate of efflux of certain kinase from muscle has been made, indicating that young ambulant patients with Duchenne muscular dystrophy have a grossly elevated muscle creatine kinase efflux (495.0 +/- 61.3 IU/kg muscle/hr) compared to control subjects (1.4 +/- 0.5 IU/kg muscle/hr).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3561434     DOI: 10.1002/mus.880100105

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  Exercise-induced muscle damage and adaptation.

Authors:  C B Ebbeling; P M Clarkson
Journal:  Sports Med       Date:  1989-04       Impact factor: 11.136

Review 2.  Mechanisms of resistance to pathogenesis in muscular dystrophies.

Authors:  J P Infante; V A Huszagh
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

3.  Myoglobin is a sensitive marker of increased muscle membrane vulnerability.

Authors:  M F Driessen-Kletter; G J Amelink; P R Bär; J van Gijn
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

4.  Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy.

Authors:  Zheng Fan; Keith Kocis; Robert Valley; James F Howard; Manisha Chopra; Hongyu An; Weili Lin; Joseph Muenzer; William Powers
Journal:  Mol Ther       Date:  2011-07-19       Impact factor: 11.454

Review 5.  The membrane hypothesis of Duchenne muscular dystrophy: quest for functional evidence.

Authors:  O F Hutter
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

6.  Exercise-induced necrotic muscle damage and enzyme release in the four days following prolonged submaximal running in rats.

Authors:  J Komulainen; V Vihko
Journal:  Pflugers Arch       Date:  1994-10       Impact factor: 3.657

7.  High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% Saline.

Authors:  Zheng Fan; Keith Kocis; Robert Valley; James F Howard; Manisha Chopra; Yasheng Chen; Hongyu An; Weili Lin; Joseph Muenzer; William Powers
Journal:  Hum Gene Ther       Date:  2015-07-30       Impact factor: 5.695

8.  Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy.

Authors:  Donovan J Lott; Tanja Taivassalo; Korey D Cooke; Hyunjun Park; Zahra Moslemi; Abhinandan Batra; Sean C Forbes; Barry J Byrne; Glenn A Walter; Krista Vandenborne
Journal:  Muscle Nerve       Date:  2020-12-22       Impact factor: 3.852

9.  Serum Enzyme Profiles Differentiate Five Types of Muscular Dystrophy.

Authors:  Yuling Zhu; Huili Zhang; Yiming Sun; Yaqin Li; Langhui Deng; Xingxuan Wen; Huaqiao Wang; Cheng Zhang
Journal:  Dis Markers       Date:  2015-04-29       Impact factor: 3.434

10.  Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.

Authors:  Adam J Bittel; Sen Chandra Sreetama; Daniel C Bittel; Adam Horn; James S Novak; Toshifumi Yokota; Aiping Zhang; Rika Maruyama; Kenji Rowel Q Lim; Jyoti K Jaiswal; Yi-Wen Chen
Journal:  Int J Mol Sci       Date:  2020-08-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.